Results 41 to 50 of about 72,950 (205)

Direct oral anticoagulant blood level monitoring in daily practice

open access: yesThrombosis Update, 2021
Introduction: Routine monitoring is not required in direct oral anticoagulant (DOAC) treatment, yet it is frequently performed. Guidance on the interpretation and management of DOAC level measurements is lacking and it is key to investigate which ...
R. Bavalia   +10 more
doaj   +1 more source

Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation) [PDF]

open access: yes, 2016
Introduction: Atrial fibrillation is an independent risk factor of thromboembolism. Women with atrial fibrillation are at a higher overall risk for stroke compared to men with atrial fibrillation. The aim of this study was to evaluate for sex differences
Abdul-Rahim, Azmil   +72 more
core   +1 more source

Reversal of direct oral anticoagulants

open access: yesVascular Health and Risk Management, 2017
Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for ...
X-Y, Zhang, M J, Desborough, S, Shapiro
openaire   +7 more sources

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

open access: yes, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P   +5 more
core   +1 more source

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

open access: yes, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?

open access: yesDiagnostics, 2023
Atrial fibrillation is frequently diagnosed in patients with liver cirrhosis, especially in those with non-alcoholic steatohepatitis or alcoholic etiology.
Irina Gîrleanu   +16 more
doaj   +1 more source

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

open access: yes, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

Bridging therapy according to new clinical guidelines: A review

open access: yesConsilium Medicum, 2022
In modern world it is really important to know how to manage patients taking anticoagulant or antiplatelet therapy. There is an increasing number of patients, who have gone through PCI or any other cardiac intervention and who also need another surgery ...
Tatiana A. Pavlenko   +2 more
doaj   +1 more source

The relationships between vitamin K and cognition: a review of current evidence [PDF]

open access: yes, 2019
Vitamin K is a fat-soluble nutrient discovered in 1935 and its role in blood coagulation has been thoroughly explored. In recent years, studies conducted in vitro and on animals highlighted vitamin K involvement in brain cells development and survival ...
Alisi, Ludovico   +7 more
core   +2 more sources

Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real‐World Practice Mirrors Guideline Recommendations

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background For more than a decade, guidelines have recommended a limited 3 months of anticoagulation for the treatment of provoked venous thromboembolism (VTE).
Elizabeth Joyce   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy